Table 4.
Correlations between the USP3 and EPHA2 expression levels and clinical characteristics.
| Characteristics | Total (n = 34) | USP3 | P value | EPHA2 | P value | ||
|---|---|---|---|---|---|---|---|
| Low | High | Low | High | ||||
| Age (year) | 0.141 | 0.724 | |||||
| <18 | 21 | 6 | 15 | 10 | 11 | ||
| ≥18 | 13 | 7 | 6 | 7 | 6 | ||
| Gender | 0.183 | 0.716 | |||||
| Male | 16 | 8 | 8 | 7 | 9 | ||
| Female | 18 | 5 | 13 | 9 | 9 | ||
| Metastasis | 0.001 | 0.039 | |||||
| Positive | 17 | 11 | 6 | 11 | 6 | ||
| Negative | 17 | 2 | 15 | 5 | 12 | ||
| Tumor size (cm3) | 0.092 | 0.595 | |||||
| <10 | 10 | 6 | 4 | 4 | 6 | ||
| ≥10 | 24 | 7 | 17 | 12 | 12 | ||
| Clinical stage | 0.042 | 0.017 | |||||
| I&II | 16 | 9 | 7 | 11 | 5 | ||
| III&IV | 18 | 4 | 14 | 5 | 13 | ||
| Tumor site | 0.961 | 0.153 | |||||
| Limb | 26 | 10 | 16 | 14 | 12 | ||
| Other | 8 | 3 | 5 | 2 | 6 | ||